When numb feet make walking feel uncertain, “exercise more” is not much of a plan. The useful question is more specific: what kind of rehabilitation can help someone function better—and does it require specialized equipment?
Our neuropathy overview covers supplements and prevention. Here, I want to separate a different question: rehabilitation after neuropathy is already present. A newer breast cancer study helps sharpen that conversation.
Evidence at a glance
Population: breast cancer survivors with persistent chemotherapy-related neuropathy. Intervention: supervised vibration-based resistance training versus conventional aerobic and resistance exercise. Signal: improvements over time in both groups; no significant difference in the main neuropathy outcome. Bottom line: rehabilitation deserves discussion, but this study does not justify promising nerve repair or buying a vibration platform.
What the 2026 trial actually compared
The sensi-ex randomized trial, published in August 2026, assigned 44 survivors to 12 weeks of supervised whole-body vibration resistance training or conventional aerobic and resistance training. Assessments continued through six months.
Neuropathy symptom burden improved over time in both groups, without a significant between-group difference on the primary outcome. Conventional training showed greater improvements in strength, mobility and neuropathy-related functional disability. Both approaches were reported as feasible and well tolerated.
The key limitation: there was no non-exercise control group. Recovery over time, expectations and professional attention could contribute. Nor does “no significant difference” establish that the approaches are equivalent. The small study cannot tell us how many people will experience a personally meaningful benefit.
How this fits the wider evidence
A 2025 systematic review included 12 studies with 928 participants. Five studies using the same neuropathy questionnaire produced a pooled standardized effect of 0.50 favoring exercise. That is a moderate statistical effect—not a 50% reduction in symptoms. Programs varied, so the result does not identify one universally best routine or guarantee that numbness disappears.
Prevention is another question. The 2024 STOP trial studied supervised sensorimotor or vibration training during oxaliplatin or vinca-alkaloid treatment. Its encouraging prevention findings cannot simply be transferred to longstanding taxane neuropathy. People with unstable bone metastases, acute leg thrombosis and certain serious cardiac conditions were excluded.
The 2020 ASCO guideline found insufficient evidence then to recommend exercise specifically as a CIPN treatment; it supported duloxetine for painful CIPN, with limited benefit. That guidance predates these newer trials. New evidence can support a rehabilitation conversation without becoming a claim that guidelines have already changed.
A safer, more useful goal
I would judge rehabilitation by a practical goal: steadier walking, easier stairs or getting out of a chair. Function can improve without proving that damaged nerves have regenerated. None of these findings establishes better cancer control.
Ask for an oncology rehabilitation assessment before attempting unstable-surface or vibration exercises. Falls, reduced sensation, bone disease and cardiovascular limitations change what is appropriate. New weakness or worsening symptoms during chemotherapy should be reported promptly, not worked through. Treatment-dose decisions remain with the oncology team.
Questions for the care team
Could a physical therapist assess my balance, strength and fall risk? Would conventional supervised exercise meet my needs without special equipment? What outcome will we track, and when will we reassess? If pain is the main problem, what should be offered alongside rehabilitation?
Evidence checked October 17, 2026. Educational review, not individualized medical advice. Research doses and schedules are not personal prescriptions. Explore the Missing Script article library and the podcast—coming soon.
